Carlo Merkel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7269400/publications.pdf

Version: 2024-02-01

66315 76872 5,839 109 42 74 citations h-index g-index papers 112 112 112 3871 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Incidence and natural history of small esophageal varices in cirrhotic patients. Journal of Hepatology, 2003, 38, 266-272.	1.8	466
2	Nutrition and survival in patients with liver cirrhosis. Nutrition, 2001, 17, 445-450. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal	1.1	454
3	varices in cirrhosis 1 1Members of the Gruppo Triveneto per l'Ipertensione Portale are as follows. Steering committee: A. Gatta and C. Merkel (University of Padua, Padua, Italy); V. Donadon (General) Tj ETQq1 1 Tremolada (General Hospital of Belluno, Belluno, Italy): and G. Marin (General Hospital of Dolo, Dolo,) Ti ETOo1 1	0.0	207
4	Clinical features and survivial of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests. Hepatology, 1999, 29, 1662-1667.	3.6	230
5	Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients. Journal of Hepatology, 2001, 35, 37-45.	1.8	226
6	The Hemodynamic Response to Medical Treatment of Portal Hypertension as a Predictor of Clinical Effectiveness in the Primary Prophylaxis of Variceal Bleeding in Cirrhosis. Hepatology, 2000, 32, 930-934.	3.6	224
7	Prognostic usefulness of hepatic vein catheterization in patients with cirrhosis and esophageal varices. Gastroenterology, 1992, 102, 973-979.	0.6	177
8	Interobserver and interquipment variability of echo-doppler examination of the portal vein: Effect of a cooperative training program. Hepatology, 1995, 21, 428-433.	3.6	152
9	Hepatic arterial resistance in cirrhosis with and without portal vein thrombosis: Relationships with portal hemodynamics. Gastroenterology, 1995, 108, 1152-1158.	0.6	141
10	The animal naming test: An easy tool for the assessment of hepatic encephalopathy. Hepatology, 2017, 66, 198-208.	3.6	135
11	Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Hepatology, 2000, 31, 324-329.	3.6	127
12	Prognostic Indicators of Risk for First Variceal Bleeding in Cirrhosis: A Multicenter Study in 711 Patients To Validate and Improve The North Italian Endoscopic Club (Niec) Index. American Journal of Gastroenterology, 2000, 95, 2915-2920.	0.2	109
13	Interobserver and interequipment variability of hepatic, splenic, and renal arterial Doppler resistance indices in normal subjects and patients with cirrhosis. Journal of Hepatology, 1997, 27, 986-992.	1.8	104
14	Renal vasoconstriction in cirrhosis evaluated by duplex doppler ultrasonography. Hepatology, 1993, 17, 219-224.	3.6	100
15	Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites. Hepatology, 1994, 19, 72-79.	3.6	100
16	Natural History of Cirrhotic Patients With Small Esophageal Varices: A Prospective Study. American Journal of Gastroenterology, 2000, 95, 503-508.	0.2	99
17	Change in portal flow after liver transplantation: Effect on hepatic arterial resistance indices and role of spleen size. Hepatology, 2002, 35, 601-608.	3.6	95
18	Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis. Journal of Hepatology, 2008, 48, S93-S103.	1.8	94

#	Article	IF	CITATIONS
19	Depression, anxiety and alexithymia symptoms are major determinants of health related quality of life (HRQoL) in cirrhotic patients. Metabolic Brain Disease, 2013, 28, 239-243.	1.4	92
20	Prognostic significance of portal hemodynamics in patients with compensated cirrhosis. Journal of Hepatology, 1993, 17, 56-61.	1.8	90
21	Prognostic value of galactose elimination capacity, aminopyrine breath test, and ICG clearance in patients with cirrhosis. Digestive Diseases and Sciences, 1991, 36, 1197-1203.	1.1	86
22	A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients. Hepatology, 1991, 14, 231-236.	3.6	85
23	Sleep-wake abnormalities in patients with cirrhosis. Hepatology, 2014, 59, 705-712.	3.6	83
24	Clinical significance of the evaluation of hepatic reticuloendothelial removal capacity in patients with cirrhosis. Hepatology, 1994, 19, 628-634.	3.6	79
25	Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis. Clinical Gastroenterology and Hepatology, 2020, 18, 313-327.e6.	2.4	74
26	Doppler sonography and hepatic vein catheterization in portal hypertension: assessment of agreement in evaluating severity and response to treatment. Journal of Hepatology, 1998, 28, 622-630.	1.8	66
27	Noninvasive grading of the severity of portal hypertension in cirrhotic patients by echo-color-Doppler. Ultrasound in Medicine and Biology, 2001, 27, 901-907.	0.7	63
28	Cognitive impairment and electroencephalographic alterations before and after liver transplantation: What is reversible? Liver Transplantation, 2014, 20, 977-986.	1.3	63
29	Carbon Monoxide-Mediated Activation of Large-Conductance Calcium-Activated Potassium Channels Contributes to Mesenteric Vasodilatation in Cirrhotic Rats. Journal of Pharmacology and Experimental Therapeutics, 2007, 321, 187-194.	1.3	62
30	Nutritional and prognostic significance of insulin-like growth factor 1 in patients with liver cirrhosis. Nutrition, 1997, 13, ν -190.	1.1	59
31	Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. Digestive and Liver Disease, 2016, 48, 455-467.	0.4	57
32	Effects of isosorbide dinitrate on portal hypertension in alcoholic cirrhosis. Journal of Hepatology, 1987, 4, 174-180.	1.8	55
33	Visual attention in cirrhotic patients: A study on covert visual attention orienting. Hepatology, 1998, 27, 1517-1523.	3.6	54
34	Covert hepatic encephalopathy: Agreement and predictive validity of different indices. World Journal of Gastroenterology, 2014, 20, 15756.	1.4	50
35	Vasoactive factors and hemodynamic mechanisms in the pathophysiology of portal hypertension in cirrhosis. Molecular Aspects of Medicine, 2008, 29, 119-129.	2.7	48
36	Long-term follow-up study of adult patients with non-cirrhotic obstruction of the portal system: comparison with cirrhotic patients. Journal of Hepatology, 1992, 15, 299-303.	1.8	47

#	Article	IF	Citations
37	Electroencephalography in Patients With Cirrhosis. Gastroenterology, 2011, 141, 1680-1689.e2.	0.6	47
38	The Influence of Environmental Factors on Sleep Quality in Hospitalized Medical Patients. Frontiers in Neurology, 2014, 5, 267.	1.1	47
39	Hemodynamic changes of systemic, hepatic, and splenic circulation following triglycyl-lysin-vasopressin administration in alcoholic cirrhosis. Digestive Diseases and Sciences, 1988, 33, 1103-1109.	1.1	43
40	Comparison between two high-dose methylprednisolone schedules in the treatment of acute hepatic cellular rejection in liver transplant recipients: A controlled clinical trial. Liver Transplantation, 2002, 8, 527-534.	1.3	43
41	SERPINB3 modulates TGF- \hat{l}^2 expression in chronic liver disease. Laboratory Investigation, 2010, 90, 1016-1023.	1.7	43
42	Hepatic venous pressure gradient measurement in clinical hepatology. Digestive and Liver Disease, 2011, 43, 762-767.	0.4	43
43	Effects of nadolol treatment on renal and hepatic hemodynamics and function in cirrhotic patients with portal hypertension. American Heart Journal, 1984, 108, 1167-1172.	1.2	42
44	Visceral fistula as a complication of endoscopic treatment of esophageal and gastric varices using isobutyl-2-cyanoacrylate: report of two cases. Gastrointestinal Endoscopy, 2000, 52, 267-270.	0.5	42
45	Arterioportal Fistulas in Patients with Liver Cirrhosis: Usefulness of Color Doppler US for Screening. Radiology, 2000, 216, 738-743.	3.6	40
46	Prognostic Benefit of the Addition of a Quantitative Index of Hepatic Encephalopathy to the MELD score: the MELDâ€EEG. Liver International, 2015, 35, 58-64.	1.9	40
47	Endoscopic screening for esophageal varices in cirrhotic patients. Hepatology, 2002, 35, 501-502.	3.6	38
48	Excessive daytime sleepiness and hepatic encephalopathy: it is worth asking. Metabolic Brain Disease, 2013, 28, 245-248.	1.4	37
49	Chronic Kidney Disease After Liver Transplantation. Transplantation, 2013, 95, 1148-1153.	0.5	35
50	Importance of the 1-month-effect of nadolol on portal pressure in predicting failure of prevention of rebleeding in cirrhosis. Journal of Hepatology, 1991, 12, 124-125.	1.8	33
51	Hypophosphatemia and renal tubular dysfunction in alcoholics. Gastroenterology, 1991, 100, 502-512.	0.6	31
52	Simple tools for complex syndromes: A three-level difficulty test for hepatic encephalopathy. Digestive and Liver Disease, 2012, 44, 957-960.	0.4	31
53	Long-term effect of nadolol or nadolol plus isosorbide-5-mononitrate on renal function and ascites formation in patients with cirrhosis. Hepatology, 1995, 22, 808-813.	3.6	30
54	Effects of chronic therapy with nadolol on portal hemodynamics and on splanchnic impedance indices using Doppler sonography: comparison between acute and chronic effects. Journal of Hepatology, 1997, 26, 305-311.	1.8	30

#	Article	IF	CITATIONS
55	Acute Liver Rejection: Accuracy and Predictive Values of Doppler US Measurements—Initial Experience. Radiology, 2005, 235, 651-658.	3.6	30
56	Nutritional and prognostic significance of serum hypothyroxinemia in hospitalized patients with liver cirrhosis. Journal of Hepatology, 1998, 28, 115-121.	1.8	29
57	Different hemodynamic patterns of alcoholic and viral endstage cirrhosis: Analysis of explanted liver weight, degree of fibrosis and splanchnic Doppler parameters. Scandinavian Journal of Gastroenterology, 2007, 42, 256-262.	0.6	29
58	Variability of atrial natriuretic peptide plasma levels in ascitic cirrhotics: Pathophysiological and clinical implications. Hepatology, 1992, 16, 1389-1394.	3.6	26
59	Clinical significance of worsening portal hypertension during long-term medical treatment in patients with cirrhosis who had been classified as early good-responders on haemodynamic criteria. Journal of Hepatology, 2010, 52, 45-53.	1.8	26
60	A Simplified Psychometric Evaluation for the Diagnosis of Minimal Hepatic Encephalopathy. Clinical Gastroenterology and Hepatology, 2011, 9, 613-616.e1.	2.4	26
61	Reversal of hepatic myelopathy after liver transplantation: Fifteen plus one. Liver Transplantation, 2010, 16, 1336-1337.	1.3	24
62	Value of Prealbumin Plasma Levels as Liver Test. Digestion, 1987, 37, 72-78.	1.2	22
63	lgM-Linked SerpinB3 and SerpinB4 in Sera of Patients with Chronic Liver Disease. PLoS ONE, 2012, 7, e40658.	1.1	22
64	Redistribution of renal blood flow in patients with liver cirrhosis. Journal of Hepatology, 1986, 2, 253-261.	1.8	21
65	Increased myoendothelial gap junctions mediate the enhanced response to epoxyeicosatrienoic acid and acetylcholine in mesenteric arterial vessels of cirrhotic rats. Liver International, 2011, 31, 881-890.	1.9	21
66	Substrate availability other than glucose in the brain during euglycemia and insulin-induced hypoglycemia in dogs. Metabolism: Clinical and Experimental, 1990, 39, 46-50.	1.5	20
67	Confounders in the detection of minimal hepatic encephalopathy: a neuropsychological and quantified <scp>EEG</scp> study. Liver International, 2015, 35, 1524-1532.	1.9	19
68	Relationship between portal blood flow measured by image-directed doppler ultrasonography and hepatic blood flow measured by indocyanine green constant infusion in patients with cirrhosis. Journal of Clinical Ultrasound, 1995, 23, 297-303.	0.4	18
69	Haemodynamic effects of propranolol, octreotide and their combination during fasting and post-prandial splanchnic hyperaemia in patients with cirrhosis. European Journal of Gastroenterology and Hepatology, 2001, 13, 163-169.	0.8	17
70	The use of human albumin millimicrospheres tagged with 99mTc in the evaluation of the removal capacity of the reticuloendothelial system. European Journal of Nuclear Medicine and Molecular Imaging, 1987, 13, 254-7.	2.2	15
71	Clinical, neuropsychological and neurophysiological indices and predictors of hepatic encephalopathy (HE). Liver International, 2021, 41, 1070-1082.	1.9	15
72	Should we routinely measure portal pressure in patients with cirrhosis, using hepatic venous pressure gradient (HVPG) as guidance for prophylaxis and treatment of bleeding and re-bleeding? Yes!. European Journal of Internal Medicine, 2011, 22, 1-4.	1.0	14

#	Article	IF	CITATIONS
73	Visual attention orienting in liver cirrhosis without overt hepatic encephalopathy. Metabolic Brain Disease, 1995, 10, 335-345.	1.4	13
74	Effect of chronic treatment with nadolol plus isosorbide mononitrate on liver blood flow and liver metabolic activity in cirrhosis. European Journal of Gastroenterology and Hepatology, 1999, 11, 1221-1226.	0.8	12
75	Bright Times for Patients With Cirrhosis and Delayed Sleep Habits: A Case Report on the Beneficial Effect of Light Therapy. American Journal of Gastroenterology, 2011, 106, 2048-2049.	0.2	12
76	Specificity of squamous cell carcinoma antigen (SCCA)â€IgM detection in patients with HCV infection and rheumatoid factor seropositivity. Journal of Medical Virology, 2013, 85, 1005-1008.	2.5	12
77	SERPINB3 is associated with longer survival in transgenic mice. Scientific Reports, 2013, 3, 3056.	1.6	12
78	Covert Hepatic Encephalopathy: Does the Mini-Mental State Examination Help?. Journal of Clinical and Experimental Hepatology, 2014, 4, 89-93.	0.4	12
79	Spontaneous portosystemic shunts in cirrhosis: Detection, implications, and clinical associations. Digestive and Liver Disease, 2021, 53, 1468-1475.	0.4	12
80	Effects of iloprost, a prostacyclin analog derivative, on renal plasma flow, renal function, and renin-aldosterone system in humans. Clinical Pharmacology and Therapeutics, 1988, 44, 211-216.	2.3	11
81	The Hunter and the Pianist. Journal of Clinical Gastroenterology, 2011, 45, 563-566.	1.1	11
82	Can we predict the first variceal bleeding in the individual patient with cirrhosis and esophageal varices?. Journal of Hepatology, 1991, 13, 378.	1.8	10
83	Hepatitis C virus reinfection in liver transplant patients: Evaluation of liver damage progression with echo-color doppler. Liver Transplantation, 2008, 14, 616-624.	1.3	10
84	Heme oxygenase regulates renal arterial resistance and sodium excretion in cirrhotic rats. Journal of Hepatology, 2011, 54, 258-264.	1.8	10
85	Liver Fibrosis and Steatosis in Alström Syndrome: A Genetic Model for Metabolic Syndrome. Diagnostics, 2021, 11, 797.	1.3	9
86	A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients. Hepatology, 1991, 14, 231-236.	3.6	9
87	Attention: Minimal hepatic encephalopathy and road accidents. Hepatology, 2012, 55, 985-987.	3.6	8
88	Clinical Significance of Cholelithiasis in Patients with Decompensated Cirrhosis. Journal of Clinical Gastroenterology, 1990, 12, 538-541.	1.1	7
89	Nonselective β-blockers plus nitrates in portal hypertension: An open question. Hepatology, 2003, 37, 1254-1256.	3.6	6
90	Cost-effectiveness analysis of beta-blockersvsendoscopic surveillance in patients with cirrhosis and small varices. World Journal of Gastroenterology, 2014, 20, 10464.	1.4	6

#	Article	IF	Citations
91	Encephalopathy or hepatic encephalopathy?. Journal of Hepatology, 2012, 57, 928-929.	1.8	5
92	Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites. Hepatology, 1994, 19, 72-79.	3.6	5
93	Renal Haemodynamics in Essential Hypertension Assessed by 133-Xenon Washout and Selective Renal Angiography. Angiology, 1982, 33, 818-824.	0.8	4
94	The cirrhotic patient with no varices and with small varices. , 2004, , 271-276.		4
95	d-Sorbitol clearance. Digestive Diseases and Sciences, 1988, 33, 1341-1341.	1.1	3
96	Circadian variation in the frequency of acute variceal bleeding in cirrhosis. Journal of Hepatology, 1994, 21, 912-913.	1.8	3
97	Adding beta-blockers to sclerotherapy in the prevention of variceal rebleeding: a meta-analysis assessment. Journal of Hepatology, 1994, 21, 918-919.	1.8	3
98	Session 3: Prevention of the Formation of Varices (Pre-Primary Prophylaxis)., 0,, 103-151.		3
99	A short cut to predict the clinical response to beta-blocker therapy in cirrhosis?. Journal of Hepatology, 2009, 51, 268-270.	1.8	2
100	Primary Prophylaxis of Bleeding from Esophageal Varices in Cirrhosis. Journal of Clinical and Experimental Hepatology, 2013, 3, 198-203.	0.4	2
101	Clinical value of asterixis in 374 well-characterised patients with cirrhosis and varying degree of hepatic encephalopathy. Digestive and Liver Disease, 2020, 52, 235-236.	0.4	2
102	Clinical pharmacology of splanchnic circulation in cirrhosis. Pharmacological Research, 1990, 22, 235-252.	3.1	1
103	Optimizing the time-frame for the definition of bleeding-related death after acute variceal bleeding in cirrhosis. European Journal of Gastroenterology and Hepatology, 1996, 8, 75-80.	0.8	1
104	Prevention of the Formation and Growth of Esophageal Varices. , 2014, , 55-61.		1
105	Training of Italian emergency medicine residents in prehospital emergency medicine: state of the art and perspectives of improvement. Internal and Emergency Medicine, 2020, 15, 519-522.	1.0	1
106	Statistical methods for predicting variceal hemorrhage. Gastroenterology, 1992, 102, 1094-1095.	0.6	0
107	Secondary prophylaxis in patients who have experienced portal hypertensive bleeding. Clinical Liver Disease, 2012, 1, 155-157.	1.0	0
108	EASL Recognition Awardee 2012. Journal of Hepatology, 2012, 57, 239-240.	1.8	0

ARTICLE IF CITATIONS

109 Introduction: Prevention of Decompensation Versus Prevention of First Bleeding., 2016, , 195-204. 0